In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.70, marking a -3.29% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%.

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion plans to present updated data from the TUPELO trial in an upcoming webinar scheduled for December 8, 2025. This presentation will provide further insights into the drug’s safety and efficacy ...

Java 26, due in March with structured concurrency, lazy constants, AOT object caching, and primitive types in patterns, instanceof, and switch, has entered a second rampdown phase for bug fixes. Java ...

CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...

The megalithic site of Gunung Padang in the highlands of western Java was constructed some 2,000 years ago over the course of several generations. Similar stone monuments are found across the ...

New Rust release brings major improvements to musl’s DNS resolver and tweaks the standard library to aid global allocators.

Many developers share their LeetCode solutions on GitHub. Look for repositories that are well-organized by topic or problem number, have clear explanations, and show good code quality. Some popular ...